News und Analysen
Ending Obamacare's Individual Mandate Would All but Kill an Already Compromised Law
The winds of change are in the air in Washington, and it has absolutely nothing to do with turkey dinners and pumpkin-spiced lattes. The long-awaited tax reform from Republicans, the current....
Ending Obamacare's Individual Mandate Would All but Kill an Already Compromised Law
The winds of change are in the air in Washington, and it has absolutely nothing to do with turkey dinners and pumpkin-spiced lattes. The long-awaited tax reform from Republicans, the current....
3 Biotech Stocks That Soared: Are They Buys?
Some of the biggest moves week in and week out come from biotech stocks. Whether it's a financial surprise, a positive clinical-trial update, regulatory approval, or even just rumors of....
What’s Next for Nektar Therapeutics?
Nektar Therapeutics (NASDAQ: NKTR) has a lot on its plate. The company's advancing its lead drug candidate, NKTR-181, to the FDA for use in chronic pain and its pipeline crisscrosses....
Is Loxo Oncology's Deal With Bayer Bad News?
After reporting that global biopharma giant Bayer AG (NASDAQOTH: BAYRY) has inked a licensing deal for its most advanced clinical-stage drug, shares in Loxo Oncology (NASDAQ: LOXO) tumbled. Is....
3 Top Medical Device Stocks to Buy Now
Healthcare investors tend to focus all of their attention on biotechnology or pharmaceutical stocks. That's a shame, because the medical device industry has some wonderful traits that make it a....
Better Buy: Biogen Inc. vs. Gilead Sciences
Historically, Biogen (NASDAQ: BIIB) has definitely been a better stock than Gilead Sciences (NASDAQ: GILD). Whether you look at the last three, five, 10, 25 years, or even so far in 2017, Biogen....
Better Buy: Biogen Inc. vs. Gilead Sciences
Historically, Biogen (NASDAQ: BIIB) has definitely been a better stock than Gilead Sciences (NASDAQ: GILD). Whether you look at the last three, five, 10, 25 years, or even so far in 2017, Biogen....
Better Buy: Biogen Inc. vs. Gilead Sciences
Historically, Biogen (NASDAQ: BIIB) has definitely been a better stock than Gilead Sciences (NASDAQ: GILD). Whether you look at the last three, five, 10, 25 years, or even so far in 2017, Biogen....
3 Reasons Novavax Stock Could Double in 2018
Charles Dickens' introduction to A Tale of Two Cities sort of applies to Novavax's (NASDAQ: NVAX) experience in 2017 so far: "It was the best of times, it was the worst of times..."At two....
Why Vascular Biogenics Ltd. Is Tanking Today
After the company released the pricing details of its just-announced common stock offering, shares of Vascular Biogenics (NASDAQ: VBLT), a clinical-stage biotech focused on cancer, fell 18% as of....
Can This Tiny Biotech Stock Pay Off Big for Celgene?
Celgene Corp (NASDAQ: CELG) loves cozying up to emerging biotech stocks working on next-generation medicine, and one of those collaborations is with Jounce Therapeutics (NASDAQ: JNCE). Celgene....
The 4 Largest Pure-Play Marijuana Stocks
Marijuana hasn't come by the nickname "the green rush" by accident. If we take a closer look at the performance of marijuana stocks, most have had investors seeing a lot of green over the trailing....
Here's Why Achillion Pharmaceuticals Is Soaring 19.5% Today
After Achillion Pharmaceuticals (NASDAQ: ACHN) priced its shares that Johnson & Johnson (NYSE: JNJ) is selling at $2.75 each, the company is rallying back 19.5% as of 3:15 p.m. EST.Johnson....
Genomic Health, Inc. Turns a Profit (With an Asterisk)
Genomic Health (NASDAQ: GHDX) recorded a $1.1 million profit during the third quarter, something it's been shooting for as it's improved its bottom line for each of the last nine consecutive....
Here's Why Nektar Therapeutics Is Skyrocketing 70% in November
After the company told investors that it plans to file for Food and Drug Administration approval for a drug that could disrupt the $12 billion market for opioid painkillers, Nektar Therapeutics....
Where Will Aurinia Pharmaceuticals Be in 5 Years?
Predicting the future isn't hard at all. Predicting the future accurately is a different matter altogether.I wanted to state that at the outset before attempting to predict how things will unfold....
5 Supernova Stocks That Have Flown Under the Radar: NuVasive
Last week on the Rule Breaker Investing podcast, Motley Fool co-founder David Gardner reviewed the performance of two sets of his buy-and-hold stock picks: one set with a five-year horizon, and....
Is Opko Health Inc. a Buy?
Longtime Opko Health Inc. (NASDAQ: OPK) shareholders have a lot to be upset about. Using about $1.47 billion of its own stock to acquire a big lab service provider a couple years ago was supposed....
Is Intuitive Surgical, Inc. a Buy?
What goes up must come down, right?That's probably been the hope for investors wanting to buy Intuitive Surgical (NASDAQ: ISRG) stock on a dip. So far this year, though, there hasn't been much of....
Is Intuitive Surgical, Inc. a Buy?
What goes up must come down, right?That's probably been the hope for investors wanting to buy Intuitive Surgical (NASDAQ: ISRG) stock on a dip. So far this year, though, there hasn't been much of....
Is Intuitive Surgical, Inc. a Buy?
What goes up must come down, right?That's probably been the hope for investors wanting to buy Intuitive Surgical (NASDAQ: ISRG) stock on a dip. So far this year, though, there hasn't been much of....
3 Indisputable Reasons Why AbbVie Is the Best Big Pharma Stock
What's the best big pharma stock?Of course, "best" can mean different things to different people. But with stocks, there are key metrics that can be used to determine which are better than others.....
Here's Why Sangamo Therapeutics Rose as Much as 16.3% Today
Shares of Sangamo Therapeutics (NASDAQ: SGMO) rose over 16% today after the company announced that the first patient had been dosed in a phase 1/2 trial evaluating the potential for its....
Alnylam Pharmaceuticals, Inc.'s Pipeline Progresses, Approval Next
Even though biotech Alnylam Pharmaceuticals (NASDAQ: ALNY) doesn't have any drugs on the market, it had a solid third quarter in terms of pipeline development, with a drug passing its phase 3....